SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending downwards following its earnings report, with concerns primarily focused on increased capital expenditures and debt related to AI infrastructure. Despite strong earnings, the community is discussing the company's future ability to monetize AI investments given these financial obligations. Some view the sell-off as an overreaction and a buying opportunity, while others express fears of an AI bubble.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending due to its low float and upcoming conference, where the company may share updates on its shift towards AI and high-performance computing. Community members are discussing potential short squeezes and high price targets, fueled by the company's expanding infrastructure and possible new contracts. Sentiment remains volatile, with traders closely monitoring key price levels and potential catalysts.

Black Titan Corp. was formed for the purpose of effecting a merger between Titan Pharmaceuticals Inc. and TalenTec Sdn Bhd. It intends to explore and identify viable business opportunities. The company was founded on July 11, 2024 and is headquartered in Petaling Jaya, Malaysia.

Black Titan Corp.

BTTC is trending due to its recent DAT+ risk management announcement, sparking high trading volume and volatile price action. Community discussions revolve around the potential for a short squeeze, comparisons to other stocks with similar setups, and caution due to the lack of concrete financial details in the news.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending as it approaches inclusion in the S&P 500, fueling discussions around its valuation and potential for continued gains, with some community members expressing skepticism, citing weak fundamentals, while others point to a potential short squeeze driven by high short interest and call option activity.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

TTD is trending as investors debate whether the stock's significant YTD decline represents a buying opportunity or reflects deeper concerns about competition and market share, particularly with Amazon. Community discussions revolve around potential overselling due to tax-loss harvesting, the company's fundamentals (cash, buybacks), and the CEO's performance amidst the stock's poor performance, with some suggesting leadership changes while others point to potential for a rebound in 2026 due to political ad spend.

AXIL Brands, Inc. engages in the manufacture, market, sale and distribution of hearing and audio enhancement, and protection products. It operates through the Hearing Enhancement and Protection, and Hair Care and Skin Care segments. The Hearing Enhancement and Protection segment includes ear buds, earmuffs, ear plugs, outdoor speakers, and ear care items. The Hair Care and Skin Care segment focuses on expanding its business-to-business salon sales through its network of domestic and international distributors. The company was founded on May 21, 2015 and is headquartered in Beverly Hills, CA.

AXIL Brands Inc.

AXIL Brands is trending due to news of a national retail distribution agreement with Walmart, sparking excitement about increased market reach. Community discussions revolve around the potential for a short squeeze, given the stock's high short interest and relatively small float. Some traders are also monitoring JZXN, drawing comparisons to TGL, while others express skepticism, suggesting the hype may be overblown and the price could decline.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending as investors discuss its potential in treating cancers, particularly after positive data in prostate cancer trials, while also citing undervaluation. The community is actively discussing the possibility of a short squeeze given the high short interest. Some also speculate about potential partnerships and acquisitions in the near future, especially with a key presentation approaching.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe ($ADBE) is trending as analysts debate whether strong Q4 earnings and AI integration are enough to offset concerns about 2026 guidance and competition from firms like Figma. The community is discussing recent price target adjustments and whether the stock is currently undervalued, presenting a buying opportunity, or if it's a value trap due to broader market sentiment.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending due to a recent debt refinancing announcement, sparking mixed reactions within the community. While some view the move as a strategic advantage for potential buyout negotiations and extended financial flexibility, others express concerns about higher interest rates and management's financial decisions. Community members are actively debating the implications of the refinancing on the company's future and potential acquisition prospects.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is trending following strong Q3 earnings, optimistic revenue guidance, and an announced contract with the U.S. Navy, driving community excitement. Wedbush recently updated its rating for Planet Labs to Outperform, setting a target of $17. Investors are closely watching for a potential breakout above its 52-week high, with some anticipating a significant rally.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has entered into separate, privately negotiated exchange agreements with...

Sarepta Therapeutics, Inc. $SRPT Shares Bought by Federated Hermes Inc.

Federated Hermes Inc. grew its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 347.8% during the second quarter, according to its most recent Form 13F filing with the...

Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up - What's Next?

Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up - What's Next...

Sarepta Therapeutics (NASDAQ:SRPT) Coverage Initiated by Analysts at Wedbush

Wedbush began coverage on Sarepta Therapeutics in a research report on Tuesday. They issued an "outperform" rating and a $32.00 price target for the company...

New York State Common Retirement Fund Sells 7,923,000 Shares of Sarepta Therapeutics, Inc. $SRPT

New York State Common Retirement Fund cut its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 98.4% in the 2nd quarter, according to the company in its most recent disclosure with...

Norges Bank Buys Shares of 913,407 Sarepta Therapeutics, Inc. $SRPT

Norges Bank purchased a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities...

Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Down - Time to Sell?

Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Down - Here's Why...

Why Is Sarepta Therapeutics (SRPT) Up 26.4% Since Last Earnings Report?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

SRPT
Sarepta Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SRPT News

SRPTSarepta Therapeutics Inc